We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NuSirt Biopharma, OWL Metabolomics Partner
News

NuSirt Biopharma, OWL Metabolomics Partner

NuSirt Biopharma, OWL Metabolomics Partner
News

NuSirt Biopharma, OWL Metabolomics Partner

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NuSirt Biopharma, OWL Metabolomics Partner"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

NuSirt Biopharma and One Way Liver S.L. (OWL Metabolomics) have announced that they have initiated a strategic partnership to develop novel diagnostic tools for ongoing drug evaluation trials for NuSirt’s fatty liver drug research candidate, NS-0200. Through their research collaboration, NuSirt and OWL will evaluate drug-induced lipidomic changes in human trials for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and explore the potential of developing a unique liquid-biopsy companion diagnostic (CDx) for NS-0200.

“Millions of people have NAFLD/NASH, but there are few medical therapies available to treat them,” said Joe C. Cook, Jr., Executive Chairman and President, NuSirt Biopharma. “OWL is a leader in diagostics for liver diseases, and we are delighted to partner with its team to not only investigate our own potential new treatment, but also examine how molecular diagnostics could broadly advance the diagnosis, treatment and monitoring of these diseases.”

NuSirt has completed enrollment for their Phase 2 TRIPLN clinical trial designed to determine the effects of its patented drug technology on patients diagnosed with NAFLD/NASH. In addition to MRI-based diagnosis known as PDFF, serial patient liquid biopsy samples from trial participants will be further analyzed via OWL Metabolomics’ lipidomic signature analysis at pre-determined time intervals. “OWL Metabolomics and our team of liver research professionals are very excited to begin this important partnership with NuSirt,” said OWL’s CEO, Pablo Ortiz, MD, PhD.

“Newly developed drugs are becoming more targeted and personalized for prevalent diseases, and regulatory authorities are seeking more precise technologies in evaluating the effects of early-stage drug candidates and determining the most appropriate patient selection. We are hopeful that our novel metabolomics-based testing technology will serve as an effective surrogate marker for specific histopathological changes within the liver and help enhance the care of NASH patients and the development of effective medical therapies to treat their condition.”

Advertisement